Immunotherapy

INCYSUS THERAPEUTICS TO PRESENT AT THE 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE

Monday, April 6, 2020 - 12:00pm

NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (Incysus), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta () T cell immunotherapy for the treatment of cancers, today announced that the Company will present at the 2020 Solebury Trout Virtual Investor Conference on Tuesday, April 7th.

Key Points: 
  • NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (Incysus), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta () T cell immunotherapy for the treatment of cancers, today announced that the Company will present at the 2020 Solebury Trout Virtual Investor Conference on Tuesday, April 7th.
  • William Ho, President and Chief Executive Officer of Incysus Therapeutics, will present a company update.
  • During the 25-minute presentation, participants will be able to submit questions electronically with answers provided afterwards.
  • Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer.

Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection

Monday, April 6, 2020 - 11:00am

The series of studies, published this week in Scientific Reports , show that SSIs activate and mobilize cells of the innate immune system to enhance and reinforce immune and barrier function of target organs to treat or prevent disease.

Key Points: 
  • The series of studies, published this week in Scientific Reports , show that SSIs activate and mobilize cells of the innate immune system to enhance and reinforce immune and barrier function of target organs to treat or prevent disease.
  • The innate immune system is the first line of defense against both infectious and non-infectious threats, and it is the critical part of the immune system responsible for providing protection against new infectious agents when adaptive immune memory is lacking.
  • This primed army of innate immune cells is not only more efficient at tackling new pathogens but is also very well-equipped in clearing cancer cells and improving barrier function in the targeted organ.
  • Qu Biologics is a Vancouver-based private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies.

CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today

Friday, April 3, 2020 - 5:06pm

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification.

Key Points: 
  • CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification.
  • These are conditions where the risk of death is extremely high, yet no effective treatments exist.
  • CytoSorb has been used in more than 80,000 human treatments to date.
  • For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter .

TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day

Friday, April 3, 2020 - 12:00pm

CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quints Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, will present an update on company progress during the panel Emergence of TCRs and Next-Generation Therapies at the Goldman Sachs Cell Therapy Day on April 6, 2020 at 2:00pm ET using a virtual platform.

Key Points: 
  • CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quints Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, will present an update on company progress during the panel Emergence of TCRs and Next-Generation Therapies at the Goldman Sachs Cell Therapy Day on April 6, 2020 at 2:00pm ET using a virtual platform.
  • TCR2Therapeutics Inc.is a clinical-stage immunotherapy company developing the next generation of novel Tcell therapies for patients suffering from cancer.TCR2sproprietary T cell receptor (TCR) Fusion Construct Tcells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent ofhuman leukocyte antigens (HLA).
  • In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
  • The Companys lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies

Thursday, April 2, 2020 - 9:46pm

Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets.

Key Points: 
  • Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets.
  • Janssen will also reimburse the Company for all activities conducted under the collaboration.
  • The Company will be primarily responsible for the manufacture of collaboration candidates, the cost of which will be paid for by Janssen.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.

Company Profile for Atara Biotherapeutics, Inc.

Thursday, April 2, 2020 - 1:33pm

Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.

Key Points: 
  • Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.
  • Ataras technology platform leverages research collaborations with leading academic institutions with the Companys scientific, clinical, regulatory and manufacturing expertise.
  • The Company was founded in 2012 and is co-located in South San Francisco and Southern California.
  • For additional information about the Company, please visit atarabio.com .

Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic

Thursday, April 2, 2020 - 1:30pm

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic.
  • While this is an unprecedented time in history, Atara is working hard to ensure operational continuity to serve patients whose lives are affected by severe diseases, said Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics.
  • Atara believes that it remains on track to initiate a tab-cel biologics license application (BLA) submission for patients with EBV+ PTLD in the second half of 2020.
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.

SAB Biotherapeutics Awarded $27M Contract to Develop Novel Rapid Response Capability for U.S. Department of Defense

Tuesday, March 31, 2020 - 3:44pm

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies leveraging the native human immune response, announced today it has been awarded a contract from the U.S. Department of Defense (DoD) to develop and test a Rapid Response Antibody Program, valued at up to $27 million.

Key Points: 
  • SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies leveraging the native human immune response, announced today it has been awarded a contract from the U.S. Department of Defense (DoD) to develop and test a Rapid Response Antibody Program, valued at up to $27 million.
  • View the full release here: https://www.businesswire.com/news/home/20200331005569/en/
    SAB Biotherapeutics has a unique ability to rapidly respond to emerging threats with its proprietary human polyclonal therapeutic platform.
  • Driven by advanced genetic engineering and antibody science, SAB has developed the DiversitAb platform to naturally and rapidly produce large amounts of targeted human antibodies, without human donors.
  • Our therapies leverage the native immune response thereby providing a highly-specific match against the complexity, diversity and mutation of disease.

Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA

Tuesday, March 31, 2020 - 11:59am

Ide-cel is the first CAR T cell therapy submitted for regulatory approval to target this antigen and for multiple myeloma.

Key Points: 
  • Ide-cel is the first CAR T cell therapy submitted for regulatory approval to target this antigen and for multiple myeloma.
  • Ide-cel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy.
  • Ide-cel is being developed as part of a Co-Development, Co-Promotion and Profit Share Agreement between Bristol Myers Squibb and bluebird bio.
  • Neither Bristol Myers Squibb nor bluebird bio bears responsibility for the security or content of external websites or websites outside of their respective control.

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Monday, March 30, 2020 - 9:01pm

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019.
  • Alpine will hold a conference call and webcast to discuss results from the fourth quarter and full year 2019 on March 30, 2020 at 4:30 pm EDT.
  • To access a live webcast of the call, please visit the Investor Relations section of the Alpine Immune Sciences website at ir.alpineimmunesciences.com.
  • Secreted Immunomodulatory Proteins, SIP, Transmembrane Immunomodulatory Protein, TIP, Variant Ig Domain, vIgD and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.